Celgene’s QUAZAR AML-001 trial of CC-486 meets primary and key secondary endpoints

Image: Celgene’s QUAZAR AML-001 trial of CC-486 meets primary and key secondary endpoints in patients with newly diagnosed acute myeloid leukemia. Photo: courtesy of skeeze from Pixabay.